{
    "clinical_study": {
        "@rank": "14877", 
        "arm_group": [
            {
                "arm_group_label": "betamethasone", 
                "description": "Patients who had intra-articular injection of betamethasone"
            }, 
            {
                "arm_group_label": "Hyaluronic acid", 
                "description": "Patients who had intra-articular injection of hyaluronic acid"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the effect of intra-articular corticosteroid injection (IACI) of depot\n      preparation of betamethasone on the hypothalamic-pituitary-adrenal (HPA) axis, in patients\n      with osteoarthritis of the knee"
        }, 
        "brief_title": "Intra-articular Betamethasone and the Hypothalamic-pituitary-adrenal Axis", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Adrenal Suppression", 
        "detailed_description": {
            "textblock": "Consecutive patients attending the rheumatology or orthopedic clinic with osteoarthritic\n      knee pain, not responding satisfactorily to medical or physical therapy were allocated to\n      group-1 after consent and given IACI of 6 mg of betamethasone acetate/betamethasone sodium\n      phosphate. Following completion of this part, consecutive age- and sex-matched patients were\n      allocated to group-2 and given intra-articular injection of 60 mg of sodium hyaluronate.\n      Just prior to the knee injection and 1, 2, 3, 4 and 8 weeks later, patients had 1 \u00b5g\n      adrenocorticotropin hormone (ACTH) stimulation test. Secondary adrenal insufficiency (SAI)\n      was defined as levels of less than 18 ng/ml or a rise of < than 7 ng/ml of serum cortisol,\n      30 minutes following the ACTH stimulation test."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Osteoarthritis of the knee\n\n        Exclusion Criteria:\n\n          -  Had steroids in the last 3 months. Allergic to steroids"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with osteoarthritis of the knee and had not been onsteroids for at least 3 months"
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01799408", 
            "org_study_id": "HPA-2012"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Betamethasone-17,21-dipropionate", 
                "Betamethasone", 
                "Betamethasone sodium phosphate", 
                "Hyaluronic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 23, 2013", 
        "number_of_groups": "2", 
        "official_title": "The Effect of Intra-articular Injection of Betamethasone Acetate/Betamethasone Sodium Phosphate at the Knee Joint on the Hypothalamic-pituitary-adrenal Axis: a Case Controlled Study", 
        "other_outcome": {
            "measure": "Nadir serum cortisol level", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "overall_official": {
            "affiliation": "Nazareth Hospital", 
            "last_name": "George Habib, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Adrenal gland suupresion and inability to adequately secrete cortisol in response to stress", 
            "measure": "Adrenal Suppression", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01799408"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Nazareth Hospital, Israel", 
            "investigator_full_name": "George Habib", 
            "investigator_title": "Head rheunatology clinic", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "favorable clinical response", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "description": "Improvement of knee pain by more than 30 points according to visual analogue scale", 
                "measure": "Favorable clinical response", 
                "safety_issue": "No", 
                "time_frame": "2 months following the steroid injection"
            }
        ], 
        "source": "The Nazareth Hospital, Israel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Nazareth Hospital, Israel", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2013"
    }
}